17. Multiple system atrophy Clinical trials / Disease details
Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03753763 (ClinicalTrials.gov) | October 29, 2019 | 19/11/2018 | Safinamide for Multiple System Atrophy (MSA) | 12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSA | Multiple System Atrophy | Drug: Safinamide Methanesulfonate;Drug: Safinamide Methanesulfonate matching placebo | Zambon SpA | NULL | Completed | 30 Years | 80 Years | All | 49 | Phase 2 | Italy;Spain |
| 2 | EUCTR2018-004145-16-ES (EUCTR) | 24/07/2019 | 11/06/2019 | A study evaluating the safety and efficacy of safinamide for patients with Multiple System Atrophy | A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with possible or probable parkinsonian variant of multiple system atrophy. - Safinamide for Multiple System Atrophy | Parkinsonian variant of Multiple System Atrophy MedDRA version: 20.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xadago INN or Proposed INN: safinamide methanesulfonate Other descriptive name: SAFINAMIDE | Zambon SpA | NULL | Not Recruiting | Female: yes Male: yes | 48 | Phase 2 | Spain;Italy |